Whitepapers

Learn how Hovione, a global CDMO, has determined that the combination of Waters instrumentation and AQbD is a powerful strategy for method development that leads to better, faster, greener analytical methods, enables resource optimization, and more.

Using the Analytical Quality by Design (AQbD) approach, an Ultra High Performance Liquid Chromatography method was developed for the analysis of a mixture of metal chelating and non-chelating compounds. DryLab, Empower, and Waters systems were used to automate the method development process.

Analytical method performance is critical to ensure the quality, safety, and efficacy of pharmaceutical products. Two of the most commonly used ones are One Factor at a Time (OFAT) and Analytical Quality by Design (AQbD). In this work, a robust method for budesonide, formoterol, and related compounds was developed using a Quality by Design approach on an ACQUITY UPLC H-Class PLUS System running Empower 3 and Fusion Software.

Chromatographic methods developed to analyze pharmaceutical compounds must distinguish low-level impurities before they reach alert/action levels. Parameters such as retention, peak shape, and sensitivity are very important to successfully accomplish this. Read this app note to learn more about MaxPeak Premier Technology.

This white paper describes the use of Empower™ 3 Control Charts to facilitate the continued procedure performance verification stage of the analytical procedure lifecycle approach.

Modern approaches to analytical procedure development such as Analytical Quality-by-Design (AQbD) focus on the reliability and accuracy of the final result, encouraging Analytical Developers to understand how aspects of sampling, storage, sample preparation, personnel training, instrument parameters, and data handling might affect result reliability. Find out more about AQbD and the best tools to design and develop fit-for-purpose methods.

This infographic demonstrates about Waters’ products, support, training, and expertise for a seamless Analytical Quality by Design (AQbD) implementation in your lab.

Replace ELISA and HPLC with Octet® systems for quantitation of antibodies and recombinant therapeutic proteins. Accurate and fast assays are also easy to develop and transfer to QC and manufacturing.

The 1290 Infinity II Bio LC including High-Speed Pump, with its iron‑free flow path, is optimally suited for the conditions used in biochromatography.

This paper describes the requirements for electronic records and electronic signatures for regulated pharmaceutical organizations.

Analysis of antibody drug conjugates using hydrophobic interaction chromatography with the Agilent 1290 Infinity II Bio LC System

The Agilent Bio-Monolith rProtein A (recombinant protein A) analytical column is the latest addition to the Bio-Monolith and affinity chromatography family.

Superior resolution in size exclusion chromatography (SEC) protein separation made possible by the Agilent 1290 Infinity II Bio LC System.

The Agilent 1290 Infinity II Bio LC System is the new platform for UV and MS-based primary structure and PTMs analysis of mAbs.

This study demonstrates how to increase sample throughput for glycan characterization workflows using the Agilent AssayMAP Bravo liquid handling platform.

Peptide-mapping analysis shows excellent performance and high method compatibility compared to the Agilent 1290 Infinity II LC System.

Homogeneous environments are essential for successful bioprocesses. Using a benchtop model, we characterized system mixing dynamics and demonstrated the potential of power input and flow direction to effect system homogeneity.

Here, we demonstrate how you can reliably measure concentrations as low as 50 pg/mL of double-stranded DNA with our SpectraMax® Multi-Mode Microplate Readers and the Quant-iT Pico Green assay.

Here, Sartorius provides an overview of cell line development and the associated hurdles. We will then discuss potential solutions that form part of an effective risk-management strategy and improve productivity.